<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:ifp="http://www.ifactory.com/press" ifp-element-xpath="/*[local-name() = 'urlset' and namespace-uri() = 'http://www.sitemaps.org/schemas/sitemap/0.9']"><ifp:contentType>ARTICLE</ifp:contentType><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p237.xml</sm:loc><ifp:title>Dedication to Alan N. Houghton, MD</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p237.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Dedication to Alan N. Houghton, MD</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p281.xml</sm:loc><ifp:title>Review of Evidence-Based Support for Pretreatment Imaging in Melanoma</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p281.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Review of Evidence-Based Support for Pretreatment Imaging in Melanoma</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p250.xml</sm:loc><ifp:title>Melanoma</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p250.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Melanoma</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p239.xml</sm:loc><ifp:title>PET/CT and Occult Primary Tumors</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p239.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>PET/CT and Occult Primary Tumors</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p238.xml</sm:loc><ifp:title>Thirty Years of Advances in Melanoma</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p238.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Thirty Years of Advances in Melanoma</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p333.xml</sm:loc><ifp:title>Merkel Cell Carcinoma: A Review of Current Advances</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p333.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Merkel Cell Carcinoma: A Review of Current Advances</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p322.xml</sm:loc><ifp:title>Merkel Cell Carcinoma</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p322.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Merkel Cell Carcinoma</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p295.xml</sm:loc><ifp:title>Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p295.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Where Are We With Adjuvant Therapy of Stage III and IV Melanoma in 2009?</ifp:title></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p308.xml</sm:loc><ifp:title>Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma</ifp:title><sm:lastmod>2026-04-18</sm:lastmod></sm:url><sm:url xmlns:sm="http://www.sitemaps.org/schemas/sitemap/0.9"><sm:loc>https://harbor.dev.pubfactory.com/view/journals/jnccn/7/3/article-p308.pdf</sm:loc><sm:lastmod>2026-04-18</sm:lastmod><ifp:title>Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma</ifp:title></sm:url></urlset>
